Login to Your Account

Kyprolis fails to extend median PFS in phase III multiple myeloma study

By Michael Fitzhugh
Staff Writer

Tuesday, September 27, 2016

Amgen Inc. said a regimen of Kyprolis, melphalan and prednisone failed to extend median progression-free survival for newly diagnosed multiple myeloma patients beyond what's delivered by a similar regimen anchored instead by Takeda Oncology Co.'s Velcade.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription